Pfizer (PFE - Free Report) closed the most recent trading day at $44.20, moving +1.57% from the previous trading session. This change outpaced the S&P 500's 1.66% loss on the day. Meanwhile, the Dow lost 1.56%, and the Nasdaq, a tech-heavy index, lost 3.03%.
Prior to today's trading, shares of the drugmaker had lost 1.11% over the past month. This has was narrower than the Medical sector's loss of 1.89% and the S&P 500's loss of 2.43% in that time.
Wall Street will be looking for positivity from PFE as it approaches its next earnings report date. This is expected to be January 29, 2019. The company is expected to report EPS of $0.64, up 3.23% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $13.73 billion, up 0.18% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3 per share and revenue of $53.40 billion. These totals would mark changes of +13.21% and +1.62%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for PFE. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.43% higher within the past month. PFE currently has a Zacks Rank of #3 (Hold).
In terms of valuation, PFE is currently trading at a Forward P/E ratio of 14.51. For comparison, its industry has an average Forward P/E of 14.56, which means PFE is trading at a discount to the group.
We can also see that PFE currently has a PEG ratio of 2.19. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. PFE's industry had an average PEG ratio of 2.01 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 100, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.